Supplementary Fig. 3: LUBAC is involved in CBM complex mediated NF-κB activation pathway. a, BJAB cells expressing the indicated shRNAs were activated by anti-IgM treatment (10 μg/ml) for indicated times and analyzed by immunoblotting for the indicated proteins. b, Viability of TMD8 ABC DLBCL line expressing control or RNF31 shRNAs were treated with DMSO, ibrutinib or lenalidomide at indicated concentrations and analyzed by FACS for viable GFP+/shRNA-expressing cells over a time course.